Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options

References

• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(S1):4–13. doi: 10.1002/hep.31288
   PubMedGoogle Scholar
• West J, Card TR, Aithal GP, et al. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment Pharmacol Ther. 2017;45(7):983–990. doi: 10.1111/apt.13961
   PubMed Web of Science ®Google Scholar
• EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908–943. doi: 10.1016/j.jhep.2011.12.001
   PubMed Web of Science ®Google Scholar
• Ozakyol A. Global Epidemiology of hepatocellular carcinoma (HCC Epidemiology). J Gastrointest Cancer. 2017 Sep 19;48(3):238–240.
   PubMed Web of Science ®Google Scholar
• Garrido A, Djouder N. Cirrhosis: a questioned risk factor for hepatocellular carcinoma. Trends Cancer. 2021;7(1):29–36. doi: 10.1016/j.trecan.2020.08.005
   PubMed Web of Science ®Google Scholar
• Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer. Hepatology. 2000;32(2):228–232. doi: 10.1053/jhep.2000.9409
   PubMed Web of Science ®Google Scholar
• Acharya SK. Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol. 2014 Aug;4:S27–33. doi: 10.1016/j.jceh.2014.05.013
   PubMedGoogle Scholar
• Liu CJ, Kao JH. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc. 2007 Apr;70(4):141–145. doi: 10.1016/S1726-4901(09)70346-6
   PubMedGoogle Scholar
• Verme G, Brunetto MR, Oliveri F, et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci. 1991 Aug;36(8):1134–1136. doi: 10.1007/BF01297460
   PubMed Web of Science ®Google Scholar
• Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012 Jun;56(6):1384–1391. doi: 10.1016/j.jhep.2011.10.027
   PubMed Web of Science ®Google Scholar
• Mancebo A, González–Diéguez ML, Cadahía V, et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol. 2013 Jan;11(1):95–101. doi: 10.1016/j.cgh.2012.09.007
   PubMed Web of Science ®Google Scholar
• Heckley GA, Jarl J, Asamoah BO, et al. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer. 2011 Dec 13;11(1):446. doi: 10.1186/1471-2407-11-446
   PubMed Web of Science ®Google Scholar
• DWH H, RCL L, Chan LK, et al. Molecular pathogenesis of hepatocellular carcinoma. Liver Cancer. 2016;5(4):290–302. doi: 10.1159/000449340
   PubMed Web of Science ®Google Scholar
• Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014 Jun 28;11(6):340–349.
   PubMed Web of Science ®Google Scholar
• Yoon SK. Molecular mechanism of hepatocellular carcinoma. Hepatoma Res. 2018;4(8):42. doi: 10.20517/2394-5079.2018.23
   Google Scholar
• Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspect Med. 2008;29(1–2):130–143. doi: 10.1016/j.mam.2007.09.008
   PubMed Web of Science ®Google Scholar
• Campbell C, Wang T, McNaughton AL, et al. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat. 2021;28(3):493–507. doi: 10.1111/jvh.13452
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Wang N, Wang S, Li MY, et al. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Therapeut Adv Med Oncol. 2018;10:175883591881628. doi: 10.1177/1758835918816287
   Web of Science ®Google Scholar
• Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49(1):318–329. doi: 10.1002/hep.22704
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang J, Zhang X, et al. Cancer stem cells: a potential breakthrough in HCC-Targeted therapy. Front Pharmacol. 2020 [cited 2020 Mar 6];11:198. doi: 10.3389/fphar.2020.00198
   PubMed Web of Science ®Google Scholar
• Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer. 2017 Dec 30;16(1):4.
   PubMedGoogle Scholar
• Fang X, Yan Q, Liu S, et al. Cancer stem cells in hepatocellular carcinoma: intrinsic and Extrinsic molecular mechanisms in Stemness regulation. Int J Mol Sci. 2022 Oct 14;23(20):12327. doi: 10.3390/ijms232012327
   PubMed Web of Science ®Google Scholar
• Benabou E, Salamé Z, Wendum D, et al. Insulin receptor isoform a favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features. Cancer Lett. 2019 May;450:155–168.
   PubMed Web of Science ®Google Scholar
• Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009 Jan;49(1):318–329. doi: 10.1002/hep.22704
   PubMed Web of Science ®Google Scholar
• Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer. 2017;16(1). doi: 10.1186/s12943-016-0572-9
   PubMedGoogle Scholar
• CKY N, Piscuoglio S, Terracciano LM. Molecular classification of hepatocellular carcinoma: the view from metabolic zonation. Hepatology. 2017 Nov 29;66(5):1377–1380.
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015 May 30;47(5):505–511. doi: 10.1038/ng.3252
   PubMed Web of Science ®Google Scholar
• Gómez-Sintes R, Arias E. Chaperone-mediated autophagy and disease: implications for cancer and neurodegeneration. Mol Aspects Med. 2021;82:82. doi: 10.1016/j.mam.2021.101025
   Web of Science ®Google Scholar
• Waly Raphael S, Yangde Z, YuXiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol. 2012;2012:1–12. doi: 10.5402/2012/421673
   Google Scholar
• Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012;1(2):83–93. doi: 10.1159/000342405
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A. Signaling pathways in hepatocellular carcinoma. Oncology. 2011;81(Suppl. 1):18–23. doi: 10.1159/000333254
   PubMedGoogle Scholar
• Ngo MHT, Jeng HY, Kuo YC, et al. The role of IGF/IGF-1R signaling in hepatocellular carcinomas: stemness-related properties and drug resistance. Int J Mol Sci. 2021 Feb 16;22(4):1931. doi: 10.3390/ijms22041931
   PubMed Web of Science ®Google Scholar
• Wang H, Rao B, Lou J, et al. The function of the HGF/c-Met axis in hepatocellular carcinoma. Front Cell Dev Biol. 2020 Feb 7;8. doi:10.3389/fcell.2020.00055
   Web of Science ®Google Scholar
• Wang Z, Chen K, Jia Y, et al. Dual ARID1A/ARID1B loss leads to rapid carcinogenesis and disruptive redistribution of BAF complexes. Nat Cancer. 2020 Sep 7;1(9):909–922. doi: 10.1038/s43018-020-00109-0
   PubMedGoogle Scholar
• Wang MD, Xiang H, Zhang L, et al. Integration of OV6 expression and CD68+ tumor-associated macrophages with clinical features better predicts the prognosis of patients with hepatocellular carcinoma. Transl Oncol. 2022 Nov;25:101509.
   PubMed Web of Science ®Google Scholar
• Zhao C, Feng Q, Dou Z, et al. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin. PLoS One. 2013 Sep 11;8(9):e73860. doi: 10.1371/journal.pone.0073860
   PubMed Web of Science ®Google Scholar
• Kumar V, Rahman M, Gahtori P, et al. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opin Drug Delivery. 2021;18(6):673–694. doi: 10.1080/17425247.2021.1860939
   PubMed Web of Science ®Google Scholar
• Guan MC, Ouyang W, Wang MD, et al. Biomarkers for hepatocellular carcinoma based on body fluids and feces. World J Gastrointest Oncol. 2021;13(5): doi: 10.4251/wjgo.v13.i5.351
   Web of Science ®Google Scholar
• Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73(1):422–436. doi: 10.1002/hep.31165
   PubMed Web of Science ®Google Scholar
• Zhang Q, Rong Y, Yi K, et al. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics. 2020;10(26):12060–12071. doi: 10.7150/thno.48918
   PubMed Web of Science ®Google Scholar
• Jin X, Cai C, Qiu Y. Diagnostic value of circulating microRnas in hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer. 2019;10(20):4754–4764. doi: 10.7150/jca.32833
   PubMed Web of Science ®Google Scholar
• Zhao XF, Li N, Lin DD, et al. Circulating MicroRNA-122 for the diagnosis of hepatocellular carcinoma: a meta-analysis. Biomed Res Int. 2020;2020: doi: 10.1155/2020/5353695
   Web of Science ®Google Scholar
• Qu J, Yang J, Chen M, et al. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: a systematic review and meta-analysis. Pak J Med Sci. 2019;35(5): doi: 10.12669/pjms.35.5.685
   Web of Science ®Google Scholar
• Zeng Z, Dong J, Li Y, et al. The expression level and diagnostic value of microRNA-22 in HCC patients. Artif Cells Nanomed Biotechnol. 2020;48(1):683–686. doi: 10.1080/21691401.2019.1703723
   PubMed Web of Science ®Google Scholar
• Pascut D, Cavalletto L, Pratama MY, et al. Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals. Cancers (Basel). 2019;11(11):1773. doi: 10.3390/cancers11111773
   PubMed Web of Science ®Google Scholar
• Pratama MY, Visintin A, Crocè LS, et al. Circulatory miRNA as a biomarker for therapy response and disease-free survival in hepatocellular carcinoma. Cancers (Basel). 2020;12(10):2810. doi: 10.3390/cancers12102810
   PubMed Web of Science ®Google Scholar
• Liu C, Zhou X, Long Q, et al. Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene. Oncogene. 2021;40(2):233–245. doi: 10.1038/s41388-020-01521-7
   PubMed Web of Science ®Google Scholar
• Oh BK, Kim H, Park HJ, et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med. 2007;20(1): doi: 10.3892/ijmm.20.1.65
   PubMed Web of Science ®Google Scholar
• Lin CH, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001;61(10):4238–4243.
   PubMed Web of Science ®Google Scholar
• Huang SL, Wang YM, Wang QY, et al. Mechanisms and clinical trials of hepatocellular carcinoma immunotherapy. Frontiers In Genetics. 2021;12. 2021 Front genet.
   Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021 Aug 13;18(8):525–543. doi: 10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Laskowski T, Rezvani K. Adoptive cell therapy: living drugs against cancer. J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20200377
   PubMed Web of Science ®Google Scholar
• Gao X, Mi Y, Guo N, et al. Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. Front Immunol. 2017 Jul 6;8. doi: 10.3389/fimmu.2017.00774.
   Web of Science ®Google Scholar
• Topalian SL, Muul LM, Solomon D, et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987 Aug;102(1):127–141. doi: 10.1016/S0022-1759(87)80018-2
   PubMed Web of Science ®Google Scholar
• Ma W, Chen X, Yuan Y. T-cell-associated immunotherapy: a promising strategy for the treatment of hepatocellular carcinoma. Immunotherapy. 2017 Jun;9(7):523–525. doi: 10.2217/imt-2017-0053
   PubMed Web of Science ®Google Scholar
• Jiang SS, Tang Y, Zhang YJ, et al. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget. 2015 Dec 1;6(38):41339–41349. doi: 10.18632/oncotarget.5463
   PubMedGoogle Scholar
• First CAR-T therapy to target BCMA gets FDA nod. Nat Biotechnol. 2021 May 12;39(5):531–531. doi:10.1038/s41587-021-00929-0
   PubMedGoogle Scholar
• Sun H, Sun C, Tian Z, et al. NK cells in immunotolerant organs. Cell Mol Immunol. 2013 May 8;10(3):202–212. doi: 10.1038/cmi.2013.9
   PubMed Web of Science ®Google Scholar
• Kalathil SG, Thanavala Y. Natural killer cells and T cells in hepatocellular carcinoma and viral hepatitis: Current status and perspectives for future immunotherapeutic approaches. Cells. 2021 May 28;10(6):1332.
   PubMed Web of Science ®Google Scholar
• King C. CAR NK cell therapy for T follicular helper cells. Cell Rep Med. 2020 Apr;1(1):100009. doi: 10.1016/j.xcrm.2020.100009
   PubMedGoogle Scholar
• Watanabe K, Nishikawa H. Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies. Int Immunol. 2021 Oct 29;33(11):551–562.
   PubMed Web of Science ®Google Scholar
• Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol. 2009;50(2):388–393. doi: 10.1016/j.jhep.2008.08.022
   PubMed Web of Science ®Google Scholar
• Béland K, Lapierre P, Alvarez F. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J Gastroenterol. 2009;15(9):1025. doi: 10.3748/wjg.15.1025
   PubMed Web of Science ®Google Scholar
• Granito A, Muratori L, Lalanne C, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021;27(22):2994–3009. doi: 10.3748/wjg.v27.i22.2994
   PubMed Web of Science ®Google Scholar
• Philips CA, Rajesh S, Nair DC, et al. Hepatocellular carcinoma in 2021: an exhaustive update. Cureus. 2021. doi: 10.7759/cureus.19274
   Web of Science ®Google Scholar
• Webb GJ, Hirschfield GM, Krawitt EL, et al. Cellular and molecular mechanisms of autoimmune hepatitis. Annu Rev Pathol. 2018;13(1):247–292. doi: 10.1146/annurev-pathol-020117-043534
   PubMedGoogle Scholar
• Fedlu M. Aflatoxin and its public Health significance: a review. J Dairy Vet Sci. 2019;12(3). doi: 10.19080/JDVS.2019.12.555837
   Google Scholar
• Torres MCP, Bodini G, Furnari M, et al. Surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: universal or selective? Cancers. 2020;12(6):1422. doi: 10.3390/cancers12061422
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023 Mar;79(2):516–537. doi: 10.1016/j.jhep.2023.03.017
   PubMed Web of Science ®Google Scholar
• Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–844. doi: 10.1038/s41573-019-0037-0
   PubMed Web of Science ®Google Scholar
• Roca Suarez AA, Testoni B, Zoulim F. HBV 2021: new therapeutic strategies against an old foe. Liver Int. 2021;41(S1):15–23. doi: 10.1111/liv.14851
   PubMedGoogle Scholar
• Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1. Gastroenterology. 2004;126(7):1750–1758. doi: 10.1053/j.gastro.2004.03.018
   PubMed Web of Science ®Google Scholar
• Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol. 2011;46(8):974–990. doi: 10.1007/s00535-011-0415-9
   PubMed Web of Science ®Google Scholar
• Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014 Jun;26:78–88. doi: 10.1016/j.semcancer.2014.01.004
   PubMed Web of Science ®Google Scholar
• Jiang Y, Han Q, Zhao H, et al. The mechanisms of HBV-Induced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:435–450. doi: 10.2147/JHC.S307962
   PubMed Web of Science ®Google Scholar
• Ng KY, Chai S, Tong M, et al. C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget. 2016 Apr 26;7(17):24005–24017. doi: 10.18632/oncotarget.8209
   PubMedGoogle Scholar
• Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol. 2001 Oct 1;36(10):651–660.
   PubMed Web of Science ®Google Scholar
• Martin-Vilchez S, Lara-Pezzi E, Trapero-Marugán M, et al. The molecular and pathophysiological implications of hepatitis B X antigen in chronic hepatitis B virus infection. Rev Med Virol. 2011 Sep;21(5):315–329. doi: 10.1002/rmv.699
   PubMed Web of Science ®Google Scholar
• Ding WB, Wang MC, Yu J, et al. Hbv/pregenomic RNA increases the stemness and promotes the development of HBV-Related HCC through reciprocal regulation with Insulin-like growth factor 2 mRNA-binding protein 3. Hepatology. 2021;74(3):1480–1495. doi: 10.1002/hep.31850
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi: 10.1038/nrm3758
   PubMed Web of Science ®Google Scholar
• Kim GW, Imam H, Khan M, et al. HBV-Induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology. 2021;73(2):533–547. doi: 10.1002/hep.31313
   PubMed Web of Science ®Google Scholar
• Seo SI, Kim HS, Kim WJ, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis b virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3928. doi: 10.3748/wjg.v21.i13.3928
   PubMed Web of Science ®Google Scholar
• Li X, Guo Y, Wang X, et al. Clinical significance of serum miR-487b in HBV-related hepatocellular carcinoma and its potential mechanism. Infect Dis. 2021;53(7):546–554. doi: 10.1080/23744235.2021.1901981
   PubMed Web of Science ®Google Scholar
• de Mattos ÂZ, Debes JD, Boonstra A, et al. Current impact of viral hepatitis on liver cancer development: the challenge remains. World J Gastroenterol. 2021;27(24):3556–3567. doi: 10.3748/wjg.v27.i24.3556
   PubMed Web of Science ®Google Scholar
• Wungu CDK, Ariyanto FC, Prabowo GI, et al. Meta-analysis: association between hepatitis B virus preS mutation and hepatocellular carcinoma risk. J Viral Hepat. 2021;28(1):61–71. doi: 10.1111/jvh.13402
   PubMed Web of Science ®Google Scholar
• Rizzo GEM, Cabibbo G, Craxì A. Hepatitis B virus-associated hepatocellular carcinoma. Viruses. 2022 May 7;14(5):986.
   PubMed Web of Science ®Google Scholar
• Wang LHC, Huang W, Lai MD, et al. Aberrant cyclin a expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis. 2012;33(2):466–472. doi: 10.1093/carcin/bgr296
   PubMed Web of Science ®Google Scholar
• Shuyao W, Mingyang B, Feifei M, et al. CK19 predicts recurrence and prognosis of HBV positive HCC. J Gastrointestinal Surg. 2021;26(2):341–351. doi: 10.1007/s11605-021-05107-w
   PubMed Web of Science ®Google Scholar
• De Battista D, Zamboni F, Gerstein H, et al. Molecular signature and immune landscape of HCV-Associated hepatocellular carcinoma (HCC): differences and similarities with HBV-HCC. J Hepatocell Carcinoma. 2021;8:1399–1413. doi: 10.2147/JHC.S325959
   PubMed Web of Science ®Google Scholar
• Trehanpati N, Vyas AK. Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer. Scand J Immunol. 2017 Mar;85(3):175–181. doi: 10.1111/sji.12524
   PubMed Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019 May;68(5):916–927. doi: 10.1136/gutjnl-2018-316510
   PubMed Web of Science ®Google Scholar
• Wei T, Zhang LN, Lv Y, et al. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2014 Nov 15;5(21):10307–10317. doi: 10.18632/oncotarget.2537
   PubMedGoogle Scholar
• Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-Cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007 Jun;132(7):2328–2339. doi: 10.1053/j.gastro.2007.03.102
   PubMed Web of Science ®Google Scholar
• Yang Y, Han Q, Hou Z, et al. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol. 2017 May 30;14(5):465–475. doi: 10.1038/cmi.2016.24
   PubMed Web of Science ®Google Scholar
• Wu Y, Hao X, Wei H, et al. Blockade of T‐cell receptor with ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV‐related HCC in mice. Hepatology. 2023 Mar;77(3):965–981. doi: 10.1002/hep.32715
   PubMed Web of Science ®Google Scholar
• Martin P, Nguyen MH, Dieterich DT, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update. Clin Gastroenterol Hepatol. 2021;20(8):1766–1775. doi: 10.1016/j.cgh.2021.07.036
   PubMed Web of Science ®Google Scholar
• Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851–861. doi: 10.1016/S2468-1253(22)00165-0
   PubMed Web of Science ®Google Scholar
• Kucukoglu O, Sowa JP, Mazzolini GD, et al. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol. 2021;74(2):442–457. doi: 10.1016/j.jhep.2020.10.030
   PubMed Web of Science ®Google Scholar
• Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124–131.e1. doi: 10.1016/j.cgh.2015.07.019
   PubMed Web of Science ®Google Scholar
• Tsuneto A, Hida A, Sera N, et al. Fatty liver incidence and predictive variables. Hypertens Res. 2010;33(6):638–643. doi: 10.1038/hr.2010.45
   PubMed Web of Science ®Google Scholar
• Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16(1):1. doi: 10.4103/jcar.JCar_9_16
   PubMedGoogle Scholar
• Myers S, Neyroud-Caspar I, Spahr L, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021;3(2):100231. doi: 10.1016/j.jhepr.2021.100231
   PubMedGoogle Scholar
• Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012;56(2):769–775. doi: 10.1002/hep.25670
   PubMed Web of Science ®Google Scholar
• Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann translat Med. 2017;5(13):270–270. doi: 10.21037/atm.2017.04.41
   PubMed Web of Science ®Google Scholar
• Michelotti A, de Scordilli M, Palmero L, et al. NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome. Cells. 2021;10(8):2034. doi: 10.3390/cells10082034
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Al-Serri A, Anstee QM, Valenti L, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol. 2012;56(2):448–454. doi: 10.1016/j.jhep.2011.05.029
   PubMed Web of Science ®Google Scholar
• Eldafashi N, Darlay R, Shukla R, et al. A pdcd1 role in the genetic predisposition to nafld-hcc? Cancers (Basel). 2021;13(6):1412. doi: 10.3390/cancers13061412
   PubMed Web of Science ®Google Scholar
• Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 2016;36(3):317–324. doi: 10.1111/liv.13031
   PubMed Web of Science ®Google Scholar
• Pirazzi C, Valenti L, Motta BM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014;23(15):4077–4085. doi: 10.1093/hmg/ddu121
   PubMed Web of Science ®Google Scholar
• Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268–279. doi: 10.1016/j.jhep.2017.09.003
   PubMed Web of Science ®Google Scholar
• Kriss M, Golden-Mason L, Kaplan J, et al. Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. PLoS One. 2020;15(7):e0236353. doi: 10.1371/journal.pone.0236353
   PubMed Web of Science ®Google Scholar
• Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656–665. doi: 10.1038/nrgastro.2013.183
   PubMed Web of Science ®Google Scholar
• Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013;102(2):84–95. doi: 10.1016/j.ygeno.2013.03.007
   PubMed Web of Science ®Google Scholar
• WKK W, Zhang L, Chan MTV. Autophagy, NAFLD and NAFLD-related HCC. Adv Exp Med Biol. 2018;1061:127–138. doi: 10.1007/978-981-10-8684-7_10
   PubMed Web of Science ®Google Scholar
• Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36(1):150–155. doi: 10.1053/jhep.2002.33713
   PubMed Web of Science ®Google Scholar
• Stefan N, Häring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9(3):144–152. doi: 10.1038/nrendo.2012.258
   PubMed Web of Science ®Google Scholar
• Adolph TE, Grander C, Grabherr F, et al. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017;18(8):1649. doi: 10.3390/ijms18081649
   PubMed Web of Science ®Google Scholar
• Hoki T, Miyanishi K, Tanaka S, et al. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis. Hepatology. 2015;62(3):751–761. doi: 10.1002/hep.27774
   PubMed Web of Science ®Google Scholar
• Blaya D, Coll M, Rodrigo-Torres D, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut. 2016;65(9):1535–1545. doi: 10.1136/gutjnl-2015-311314
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Factor VM, Andersen JB, et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–3536. doi: 10.1038/onc.2009.211
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang Y, Borlak J, et al. Mechanistically linked serum miRnas distinguish between drug induced and fatty liver disease of different grades. Sci Rep. 2016;6(1):6. doi: 10.1038/srep23709
   PubMedGoogle Scholar
• Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Investig. 2012;122(8):2871–2883. doi: 10.1172/JCI63539
   PubMed Web of Science ®Google Scholar
• He Y, Hwang S, Cai Y, et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting Multiple inflammatory and oncogenic genes in hepatocytes. Hepatology. 2019;70(4):1150–1167. doi: 10.1002/hep.30645
   PubMed Web of Science ®Google Scholar
• WHO. World Health organization | hepatitis C. Bulletin of the World Health organization - fact sheet N°164. 2020.
   Google Scholar
• Cabibbo G, Petta S, Barbàra M, et al. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int. 2017;37(8):1157–1166. doi: 10.1111/liv.13357
   PubMed Web of Science ®Google Scholar
• Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology. 2019;157(5):1253–1263.e2. doi: 10.1053/j.gastro.2019.07.040
   PubMed Web of Science ®Google Scholar
• Saito T, Sugimoto M, Okumoto K, et al. Serum metabolome profiles characterized by patients with hepatocellular carcinoma associated with hepatitis B and C. World J Gastroenterol. 2016;22(27):6224. doi: 10.3748/wjg.v22.i27.6224
   PubMed Web of Science ®Google Scholar
• Zhang Y. Detection of epigenetic aberrations in the development of hepatocellular carcinoma. Methods Mol Biol. 2015;1238:709–731. doi: 10.1007/978-1-4939-1804-1_37
   PubMedGoogle Scholar
• Ahumada A, Rayón L, Usón C, et al. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: who to screen and for how long? World J Gastroenterol. 2021;27(40):6737–6749. doi: 10.3748/wjg.v27.i40.6737
   PubMed Web of Science ®Google Scholar
• Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59(4):675–683. doi: 10.1016/j.jhep.2013.05.015
   PubMed Web of Science ®Google Scholar
• Hamdane N, Jühling F, Crouchet E, et al. HCV-Induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology. 2019;156(8):2313–2329.e7. doi: 10.1053/j.gastro.2019.02.038
   PubMed Web of Science ®Google Scholar
• Akkari L, Grégoire D, Floc’h N, et al. Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors. J Hepatol. 2012;57(5):1021–1028. doi: 10.1016/j.jhep.2012.06.027
   PubMed Web of Science ®Google Scholar
• Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016;40(1):9–14. doi: 10.1016/j.clinre.2015.07.006
   PubMed Web of Science ®Google Scholar
• Domovitz T, Gal-Tanamy M. Tracking down the epigenetic footprint of hcv-induced hepatocarcinogenesis. J Clin Med. 2021;10(3):551. doi: 10.3390/jcm10030551
   PubMed Web of Science ®Google Scholar
• Zhao P, Malik S, Xing S. Epigenetic mechanisms involved in HCV-Induced hepatocellular carcinoma (HCC). Front Oncol. 2021;11: doi: 10.3389/fonc.2021.677926
   Web of Science ®Google Scholar
• Zhao W, Liu H, Liu W, et al. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol. 2006;28(5): doi: 10.3892/ijo.28.5.1081
   Web of Science ®Google Scholar
• Ke PY, Chen SSL. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Investig. 2011;121(1):37–56. doi: 10.1172/JCI41474
   PubMed Web of Science ®Google Scholar
• Jassey A, Liu CH, Changou C, et al. Hepatitis C virus non-structural protein 5A (NS5A) disrupts mitochondrial dynamics and induces mitophagy. Cells. 2019;8(4):290. doi: 10.3390/cells8040290
   PubMed Web of Science ®Google Scholar
• Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. Hepatology International. doi: 10.1007/s12072-020-10094-2
   PubMed Web of Science ®Google Scholar
• Chan AWH, Wong GLH, Chan HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol (Australia). 2017;32(3):667–676. doi: 10.1111/jgh.13536
   PubMed Web of Science ®Google Scholar
• Vongsuvanh R, van der Poorten D, George J. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the asia pacific. Hepatol Int. 2013;7(S2):823–832. doi: 10.1007/s12072-013-9453-0
   PubMedGoogle Scholar
• Febbraio MA, Reibe S, Shalapour S, et al. Preclinical models for studying NASH-Driven HCC: how useful are they? Cell Metab. 2019;29(1):18–26. doi: 10.1016/j.cmet.2018.10.012
   PubMed Web of Science ®Google Scholar
• Meroni M, Longo M, Fracanzani AL, et al. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine. 2020;57:102866. EBioMedicine. 2020. doi: 10.1016/j.ebiom.2020.102866.
   PubMed Web of Science ®Google Scholar
• Chen S, Guo H, Xie M, et al. Neutrophil: an emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol. 2021;97:107609. doi: 10.1016/j.intimp.2021.107609
   PubMed Web of Science ®Google Scholar
• Zhou SL, Zhou ZJ, Hu ZQ, et al. Tumor-associated neutrophils recruit macrophages and T-Regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology. 2016;150(7):1646–1658.e17. doi: 10.1053/j.gastro.2016.02.040
   PubMed Web of Science ®Google Scholar
• Pelusi S, Baselli G, Pietrelli A, et al. Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease. Sci Rep. 2019;9(1): doi: 10.1038/s41598-019-39998-2
   PubMedGoogle Scholar
• Ally A, Balasundaram M, Carlsen R, et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327–1341.e23. doi: 10.1016/j.cell.2017.05.046
   PubMed Web of Science ®Google Scholar
• Abdel-Moety A, Baddour N, Salem P, et al. SQSTM1 expression in hepatocellular carcinoma and relation to tumor recurrence after radiofrequency ablation. J Clin Exp Hepatol. 2022 May;12(3):774–784. doi: 10.1016/j.jceh.2021.12.001
   PubMed Web of Science ®Google Scholar
• Stumptner C, Fuchsbichler A, Zatloukal K, et al. In vitro production of Mallory bodies and intracellular hyaline bodies: the central role of sequestosome 1/p62. Hepatology. 2007;46(3):851–860. doi: 10.1002/hep.21744
   PubMed Web of Science ®Google Scholar
• Sze KM, Ho DW, Chiu Y, et al. Hepatitis B virus–telomerase reverse transcriptase promoter integration harnesses host ELF4, resulting in telomerase reverse transcriptase gene transcription in hepatocellular carcinoma. Hepatology. 2021 Jan 26;73(1):23–40. doi: 10.1002/hep.31231
   PubMed Web of Science ®Google Scholar
• Cortes E, Lachowski D, Rice A, et al. Retinoic acid receptor‐β is downregulated in hepatocellular carcinoma and cirrhosis and its expression inhibits myosin‐driven activation and durotaxis in hepatic stellate cells. Hepatology. 2019 Feb 17;69(2):785–802. doi: 10.1002/hep.30193
   PubMed Web of Science ®Google Scholar
• Kim H, Park J, Kim Y, et al. Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. Sci Rep. 2017 Aug 25;7(1):9449. doi: 10.1038/s41598-017-09691-3
   PubMedGoogle Scholar
• Jin ZL, PHXYYJDT. SUMO-specific protease SENP5 controls DNA damage response and promotes tumorigenesis in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2016 Sep;20(17):3566–3573. PMID: 27649656.
   PubMed Web of Science ®Google Scholar
• Torimura T, Ueno T, Kin M, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol. 2004 May;40(5):799–807. doi: 10.1016/j.jhep.2004.01.027
   PubMed Web of Science ®Google Scholar
• Junjie X, Songyao J, Minmin S, et al. The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer. 2012;12(1):12. doi: 10.1186/1471-2407-12-57
   PubMedGoogle Scholar
• Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–1239.e4. doi: 10.1053/j.gastro.2015.05.061
   PubMed Web of Science ®Google Scholar
• Müller M, Bird TG, Nault JC. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol. 2020;72(5):990–1002. doi: 10.1016/j.jhep.2020.01.019
   PubMed Web of Science ®Google Scholar
• Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease—one of a kind or two different enemies? Transl Gastroenterol Hepatol. 2019;4:72–72. doi: 10.21037/tgh.2019.09.01
   PubMed Web of Science ®Google Scholar
• Nahon P, Sutton A, Rufat P, et al. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology. 2009;50(5):1484–1493. doi: 10.1002/hep.23187
   PubMed Web of Science ®Google Scholar
• Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res. 2010;29(1). doi: 10.1186/1756-9966-29-18
   Google Scholar
• Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2015;2015: doi: 10.1002/14651858.CD002235.pub3
   Google Scholar
• Donohue TM. Alcohol-induced steatosis in liver cells. World J Gastroenterol. 2007;13(37):4974. doi: 10.3748/wjg.v13.i37.4974
   PubMed Web of Science ®Google Scholar
• Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol. 2019;70(2):294–304. doi: 10.1016/j.jhep.2018.12.003
   PubMed Web of Science ®Google Scholar
• Roy N, Dasgupta D, Mukhopadhyay I, et al. Genetic association and gene-gene interaction reveal genetic variations in ADH1B, GSTM1 and MnSOD independently confer risk to alcoholic liver diseases in India. PLoS One. 2016;11(3):e0149843. doi: 10.1371/journal.pone.0149843
   PubMed Web of Science ®Google Scholar
• Nakano S, Eso Y, Okada H, et al. Recent advances in immunotherapy for hepatocellular carcinoma. Cancers. 2020;12(4):775. doi: 10.3390/cancers12040775
   PubMed Web of Science ®Google Scholar